INTRODUCTION
Cyclosporin A (CS-A),1 an endecapeptide obtained from several fungal extracts, appears to be an essentially Received for publication 25 November 1980 and in revised form 30 January 1981. 1 Abbreviations used in this paper: CS-A, cyclosporin A; S-Ag, S antigen.
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T cell-specific drug (1) . It has been found to be beneficial in preventing or modulating experimental allergic encephalomyelitis, Freund's adjuvant arthritis, graft vs. host disease, reactions related to allogeneic bone marrow transplantation, and allograft rejection (2) (3) (4) (5) (6) . The retinal S antigen (S-Ag), a protein purified from mammalian retinas (7) , consistently induces with one immunizing injection, remote from the globe, a severe anterior and posterior uveitis in lower mammals and in subhuman primates (7) (8) (9) . Also, some patients with posterior uveitic conditions demonstrate in vitro cellmediated responses to this antigen (10) , thus suggesting that it may play a role in the pathogenesis of their disease. We report here the successful prevention of autoimmune uveitis in rats with CS-A. In addition, the immune responses monitored during this study provide information about cellular mechanisms in this model.
METHODS
Female Lewis rats (MA Bioproducts, Walkersville, Md.) weighing about 200 g, were immunized with a total of 30 ,ug of bovine S-Ag, prepared as outlined elsewhere (7) . The S-Ag was emulsified 1:1 in complete Freund's adjuvant (Gibco Laboratories, Grand Island Biological Co., Grand Island, N. Y.) enriched with the addition of 2.5 mg/ml of M. tuberculosis H37 RA (Difco Laboratories, Detroit, Mich.). The emulsion was injected into both hind foot pads. All animals were sacrificed 14 d after immunization. CS-A, kindly supplied by Sandoz, Ltd., was dissolved in pure olive oil, and test rats received S-Ag combined with either daily subcutaneous CS-A or pure olive oil injections into the hind quarters for 14 d starting on the day of S-Ag immunization, while others received CS-A starting on day 7 after immunization and continued daily until day 14.
Cell culture and antibody evaluation. A serum sample was taken by cardiac puncture, and popliteal draining lymph nodes from the site of S-Ag immunization were removed at the time of sacrifice. The lymph nodes were teased, the cells washed, and lymphocyte cultures prepared as described elsewhere (11) . Briefly, cultures were performed in triplicate in flat bottom Microtest II plates (Falcon Labware, Div of Becton, Dickinson & Co., Oxnard, Calif. 3 x 105 cells in 0.2 ml/well) in RPMI 1640 medium (MA Bioproducts) supplemented with 2 mM glutamine, 100 U penicillin/ml and 100 ,ug streptomycin/ml (Gibco Laboratories) and 10% heatinactivated AB+ human serum. Cultures were stimulated with S-Ag, purified protein derivative (Connaught Laboratories, Toronto, Canada) and concanavalin A (Con A, Calbiochem-Behring Corp., American Hoechst Corp., San Diego, Calif.). Tritiated thymidine 1,uCi/well, (Amersham Corp., Arlington Heights, Ill.) was added for the last 16 h of culture, which were terminated 4 d after initiation. The uptake of thymidine was measured by scintillation counting, and the results for each group are presented as the stimulation index (calculated by dividing the counts per minute [cpm] of stimulated wells by the cpm of wells containing no additive) ±SE.
Determination of the anti-S-Ag antibodies by the enzymelinked immunoassay technique was performed as reported by Rennard et al. (12) . Briefly, polystyrene plate wells (Linbro Chemical Co., Hamden, Conn.) were coated by incubation with 120 ng of S-Ag for 2 h. The reactants were added in the following order: (a) test rat sera were serially diluted and incubated 2 h. (b) The peroxidase conjugated anti-rat IgG (Miles Laboratories Inc., Elkhart, Ind.) at a 1:1,000 dilution was incubated for 1 h. (c) The substrate for the bound enzyme was also incubated for 1 h. Incubations were at 37°C in a final volume of 100 /A. The wells were washed three times after each incubation with phosphate-btuffered saline containing 0.05% Tween-20. Positive color changes were visually recorded (double blind) and compared to rat sera which were previously determined as containing or not containing anti-SAg antibody. The reported titers are an average of at least four separate sera from each treatment group.
Histologic preparationt anid graditng of iniflammiiiiation. Eyes were fixed in 10% neutral buffered formaliin and stained with hematoxylin and eosin. Histopathology was evaluated by Dr. Rodrigues without information about the protocol for treatmrent. The grade of inflammiiiiation, as outlined in referenice 7, are averages based on eyes that developecl uveitis.
RESULTS
Control rats immunized with S-Ag and given daily injections of olive oil manifested severe ocular disease by 14 d. The globes were proptotic, and an hypopyon and/ or hemorrhage was evident in the anterior chamber. Histologically, a panophthalmitis was apparent. A severe anterior chamber reaction was present with fibrin as well as acute and chronic inflammatory cells. The posterior portion of the eye showed a marked mononuclear infiltration of the retina, often destroying its normal architecture (Fig. 1) . Grading the uveitis from none (0) (4), the eyes taken from these animals were found to have an average grade 3.3 uveitis. However, the uveitis produced by S-Ag was markedly reduced in rats with CS-A (Table I) All experimental groups demonstrated good proliferative responses to concanavalin A, indicating good culture viability and responsiveness. All the groups exhibited variations in response, with no statistically significant differences apparent. However, the proliferative responses to the S-Ag were significanitly greater in rats treated with 0.5 or 5 mg/kg per d (P <0.05), as compared to S-Ag immu-nized non-CS-A treated rats. The proliferative responises to pturified proteiin derivative appeared to be depressed in rats treated with 10 mg/kg per d, but statistical analysis did not stupport that impression (P 2 0.05).
Circtulating anti-S-Ag antibodies (IgG) were found 14 d after S-Ag imnmtinization. Sera fromn CS-A treated S-Ag immnunized animals with nio evidenice of ocuilar inflammation had antibody titers simiiilar to the uinprotected group with uveitis (Table I) .
Treatment with CS-A was also founiid effective even1 when daily injectionis were started 7 Mean value of only uveitic eyes in each grouip. § P < 0.05 when compared to "nlone" grotip.
I I CS-A treatment begun 7 d after S-Ag immu-nizationi. Mitotic responises reported are the result of pooled lymlph node cells.
Enzyme-linked imnmunioassay determiniationi is the average of six in(lividual sera.
was needed to completely suppress the uveitis in all six animals by this schedutle as compared to the 10 mg/kg of CS-A needed when treatment was initiated on the day of immunization. Antibody titers were the same as the other groups reported ( The increased cell proliferation in culture to the S-Ag of lymphocytes from CS-A treated animals as compared to controls deserves comment. In groups with stimulation indexes greater than the control value, animals with aind without uveitis manifested this response. Additional kinetic experiments have tentatively shown that maximum cell-mediated responses from lymph nodes ofanimals treated with 5 mg/ kg of CS-A appear to peak abouit 14 d after S-Ag immunization. Peak cell-mediated responses from non-CS-A protected animals were seeni some four days earlier than the CS-A treated group. It has been suggested that CS-A may have a selectivity for certain T-cell sub-populations (13) (14) (15) . The delayed response to S-Ag we have seen may be a result of CS-A's effect on T cell subgroups such as helper cells, which could be concerned with the recruitment of other immunoreactive cells. An alternative or additional possibility could be that suppressor T cells are not affected or are even augmented by CSA therapy, as has been suggested to be the case in humans (15) .
The finding of similar antibody titers in unprotected and CS-A protected animals is in line with the wellestablished selectivity of this drug toward T cells (1) , and indicates the essential role of the T cell in the pathogenesis of this disease. These data indicate further that CS-A could be a new drug in the armamentarium of medications capable of altering severe ocular inflammatory reactions, which account for a significant number of visually impaired individuals.
